BIO Asia–Taiwan 2023 亞洲生技大會

BIO Asia–Taiwan 2023 亞洲生技大會

PROGRAM

2022 Focus Symposia & Workshop

​​

BIO Asia–Taiwan 2022
Focus Symposia & Workshop Agenda 

Amarex
Taiwan
Australian Office in Taipei
Taiwan Oncology Society

Cell and Gene Therapy Development Success, from Benchtop to
Marketing Authorization

DateJuly 27-31|On-demand

VenueOnline Event Platform

5 mins

Opening Remarks

Session Chair
Patrick JP Burke
Sr. Director, Business Development, Amarex Clinical Research, LLC

20 mins

Towards Closed and Automated Manufacturing of CAR T-cell therapy

Luc Henry, DPhil CEO, Limula SA

25 mins

Overcoming the Challenges of Cell & Gene Therapy Data Collection

Herman Wong, B.S.

Sr. Vice President, Information Technology, Amarex Clinical Research, LLC

20 mins

From Magical Mystery Tour to. ... Here Comes the Sun: A Stem Cell Story From the Southern Hemisphere.

Maroun Khoury, Ph.D.

Acting CEO / CSO, Cells for Cells SA

20 mins

Approaches to Overcoming Regulatory and Clinical Limitations of Cell and Gene Therapies

Chia-Hua Maggie Ho, DPhil.

Chief Operating Officer, Amarex Taiwan, LLC

Company Info

Company Name:Amarex Taiwan, LLC

Address:2F., No.19-10, Sanchong Rd., Nangang Dist, Taipei 115, Taiwan

Website:www.amarextw.com

Contact

Name:Ming-Fen Hsu

Title:Sr. Clinical Development Manager

Email:mingfenh@amarextw.com

Phone:(02) 26553391

Introduction

Amarex Taiwan, LLC began as a concept in 2003 following several years of steady growth of services provided by Amarex Clinical Research, LLC (U.S.) to Taiwanese pharma, biotech, and device companies. Shortly thereafter Amarex Taiwan was established as an affiliate organization to better serve its clients in the Pan-Pacific Region. Amarex Taiwan’s services include clinical site management, safety monitoring, and regulatory compliance for Phase I through IV trials with sites in Taiwan and the Pan-Pacific Region. In close collaboration with our U.S. affiliate, we provide regulatory services and all other trial support services including regulatory strategy development, protocol writing, data management, data analysis, and clinical study report writing. During the COVID-19 pandemic, Amarex helped companies to obtain EUA and rapid clinical trial approval from the U.S. FDA and other Regulatory Agencies around the World; including EU Competent Authorities, MHRA, Health Canada for drug, biological product, medical device and diagnostic products intended to treat and/or diagnose COVID-19.

The Australian Biotechnology Ecosystem

DateFriday 29 July, 2022 08:30-12:00

VenueRoom 703, Hall 2, Taipei Nagang Exhibition Centre

Registration Registration link

08:30-09:00

Registration and Morning Coffee

09:00-09:10

Welcome Remarks

Ms Jenny Bloomfield, Australian Representative in Taiwan

Opening Remarks

Dr Chung-hsiu Wu

Director, Biotechnology and Pharmaceutical Industries Promotion Office, MOEA

Chairman, Taiwan Bio Industry Organisation

09:10-09:20

Australia: A powerhouse for science and innovation in Biotechnology

Rhett Miller

Head of Greater China International Health Team

Trade and Investment Commissioner, Austrade

Part 1- Presentation: Australia Clinical Trials Capabilities

09:20-09:55
Topic Speaker
George Clinical – Your CRO Partner for Australia and across the Globe James Cheong
Chief Executive Officer
George Clinical
US Team capability, Phase I capability and Experiences (ANZ), NVT/PPC integration John Moller
Chief Executive Officer
Novotech
Southern Star Research: Early Phase Clinical Study Specialists Chris Stellatos, Director
Southern Star Research
Neuroscience Trials Australia (NTA): The CRO for all your neuroscience trials in Australia and beyond Kathy Skoff
Senior Business Development Manager
Neuroscience Trials Australia
Nucleus Network : Your Premier Early Phase Clinical Trial Solution Provider Across Australia and USA Jeffery Wong
Director of Business Development
Nucleus Network
Local knowledge, global network: Bioanalytical solutions for Australia and beyond Angela Luttick
EVP, Commercial
360biolabs
Conducting Clinical Trials in Australia: Corporate Structuring & R&D Incentives Blair Lucas, Partner
Acclime Australia
09:55-10:10

Q&A

Part 2- Presentations: Australian Innovative Biotech Company Presentation

10:10-10:35
Topic Speaker
MiCheck® Prostate for Detection of Aggressive Prostate Cancer Dr Brad Walsh
Chief Executive Officer
Minomic International
Discovery, development, and market authorisation of microbiome-based therapies Thomas Mitchell
Chief Executive Officer
BiomeBank
Data driven development of microbiome-based therapeutics Trent Muno
SVP Therapeutics
Microba Life Sciences
Your Australian Future: Global Talent Visa Program Pip Butler
Director Global Talent, Hong Kong and North Asia Global Australia Taskforce
10:35-10:50

Q&A

10:50-11:05

Tea Break

Part 3: Taiwan Precision Medicine Company Presentation

11:05 – 11:35
Topic Speaker
Code to cure, an enterprise cloud-native BioMed-IT platform to empower biotech and precision medicine industries to innovate at scale and speed Allen Chang
Chief Executive Officer
ATGENOMIX
One-stop services for cell-based products and bioassays Shing-Mou Lee
Chief Executive Officer & Lab Head
TACT, Executive Director
EMO Biomedicine
Universal antibody lock makes antibody drugs safer and effective Yun-Chi Lu
Chief Executive Officer
PrecisemAb Biotech
A novel nanobody-based trispecific T cell engager (Nb-TriTE) for cancer immunotherapy Shao-Chih Chiu
Chief R&D Officer
Shine-On BioMedical
Biologic drug industry pain points and how we can help to fill the gap Alan Chang, Ph.D.,
Chief Executive Officer
Taron Solutions
Research results of lung cancer urine detection technology I-Shu Lee, Ph.D.
Chief Executive Officer
VITAE Biomedical
11:35-11:50

Q&A

12:00

Event Closing

生物相似性藥品研討會:法規、健保支付與臨床應用

DateFriday 30 July, 2022 13:30-17:00

VenueRoom 702, Hall 2, Taipei Nagang Exhibition Centre

Registration separately Registration Link

13:30~14:00

報到

14:00~14:05

開場致詞

Speaker

楊志新 理事長

中華民國癌症醫學會

14:05~14:25

The Value of Biosimilars

Speaker

姜紹青 藥師

臺灣臨床藥學會學術主委/和信醫院藥劑科副主任

Moderator

謝右文 理事長

臺灣臨床藥學會

14:25~14:50

The must-knows for Biosimilars

Speaker

張端瑩 醫師

臺大醫院腫瘤部

Moderator

趙毅 主任

臺北榮民總醫院 腫瘤醫學部

14:50~15:15

Can we switch to biosimilar? How and when?

Speaker

謝燿宇 主任

衛生福利部雙和醫院 血液腫瘤科

Moderator

褚乃銘 主任

和信治癌中心醫院 血液與腫瘤內科

15:15~15:25

Break

15:25~15:55

我國生物相似性藥品健保給付政策現況與願景

Speaker

張惠萍 簡任技正

衛生福利部中央健康保險署醫審及藥材組

Moderator

譚家惠 秘書長

臺灣藥物經濟暨效果研究學會

15:55~16:25

Regulatory Considerations for Biosimilars

Speaker

陳紀勳 資深臨床小組長

財團法人醫藥品查驗中心

Moderator

蕭美玲 理事長

台灣醫藥品法規學會

16:25~16:55

Panel Discussion (with interactive response system)

Speakers

All Speakers

Moderator

楊志新 理事長

中華民國癌症醫學會

16:55~17:00

閉幕致詞

Speaker

楊志新 理事長

中華民國癌症醫學會